Aspirin Exacerbated Respiratory Disease Market Segmentation:
Treatment Type Segment Analysis
Under the treatment type, the biologic therapy dominates the segment and is poised to have a aspirin exacerbated respiratory disease market share of 43.5% by 2034. The segment is driven by superior efficacy in controlling eosinophilic inflammation related to aspirin-exacerbated respiratory disease. As per the NIH report, the data from the National Heart, Lung, and Blood Institute, biologics including dupilumab, benralizumab, and mepolizumab experience a reduction of 40.3% to 60.4% in nasal polyp size and asthma exacerbations, mainly in patients unaffected by corticosteroids. Trials funded by the NIH, such as NCT02925302, support the use of biologics in the long-term management of AERD.
End user Segment Analysis
In the end-user category, hospitals and specialty clinics have the largest revenue share and are anticipated to grow to 38.8% in 2034. The segment is driven by the function of delivering biologic therapies and managing complicated aspirin-exacerbated respiratory disease cases. The increasing use of targeted therapies like IL-4 and IL-5 inhibitors in inpatient and outpatient hospital care is being fueled by supportive reimbursement practices under Medicare and private insurance plans in developed markets, including the U.S., Canada, Germany, and Japan. Specialty clinics are experiencing a rising patient footfall with the availability of advanced diagnostic equipment and customized treatment protocols. These combined dynamics are driving a consistent move towards differentiated, value-added respiratory care in the end-user market.
Our in-depth analysis of the global aspirin exacerbated respiratory disease market includes the following segments:
|
Segment |
Subsegment |
|
Treatment Type |
|
|
Distribution Channel |
|
|
End user |
|
